Since the downregulation of PTGER3 and upregulation of MMP-2 are protective for renal diseases, the agonists of PTGER3 (including iloprost and treprostinil) and inhibitor of MMP-2 (like captopril) might be inapplicable for the treatment of DN. This evidence concerns the gene PTGER3 and liver dysplastic nodule.